Evidence map›Paper›PMID 41914495›Full record

ArticleNucleic acids research2026

Reversible RNA ADP-ribosylation on uracil bases.

Yang Lu, Li Tang, Øyvind Strømland, Chatrin Chatrin, Kang Zhu, Deeksha Munnur, Joséphine Groslambert, Petra Mikolčević, Herwig Schüler, Gyula Timinszky and 7 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yang LuSir William Dunn School of Pathology, University of Oxford, OxfordOX1 3RE, United Kingdom.
Li TangCarbohydrate-Based Drug Research Centre, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Øyvind StrømlandDepartment of Biomedicine, University of Bergen, Bergen5020, Norway.
Chatrin ChatrinSir William Dunn School of Pathology, University of Oxford, OxfordOX1 3RE, United Kingdom.
Kang ZhuSir William Dunn School of Pathology, University of Oxford, OxfordOX1 3RE, United Kingdom.
Deeksha MunnurSir William Dunn School of Pathology, University of Oxford, OxfordOX1 3RE, United Kingdom.
Joséphine GroslambertSir William Dunn School of Pathology, University of Oxford, OxfordOX1 3RE, United Kingdom.
Petra MikolčevićDivision of Molecular Biology, Ruđer Bošković Institute, Zagreb 10000, Croatia.
Herwig SchülerDivision of Biochemistry and Structural Biology, Department of Chemistry, Lund University, LundSE-22362,  Sweden.ORCID 0000-0003-4059-3501
Gyula TiminszkyLaboratory of DNA Damage and Nuclear Dynamics, Institute of Genetics, HUN-REN Biological Research Centre, Szeged 6726, Hungary.ORCID 0000-0001-6342-8985
Guillaume GabantCentre de Biophysique Moléculaire, CNRS UPR 4301, affiliated with Université d'Orléans, Orléans45071,France.
Marcin J SuskiewiczCentre de Biophysique Moléculaire, CNRS UPR 4301, affiliated with Université d'Orléans, Orléans45071,France.ORCID 0000-0002-3279-6571
Andreja MikočDivision of Molecular Biology, Ruđer Bošković Institute, Zagreb 10000, Croatia.
Vincent AucagneCentre de Biophysique Moléculaire, CNRS UPR 4301, affiliated with Université d'Orléans, Orléans45071,France.ORCID 0000-0002-2647-0188
Dragana AhelSir William Dunn School of Pathology, University of Oxford, OxfordOX1 3RE, United Kingdom.
Qiang LiuCarbohydrate-Based Drug Research Centre, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.ORCID 0000-0003-1229-7908
Ivan AhelSir William Dunn School of Pathology, University of Oxford, OxfordOX1 3RE, United Kingdom.ORCID 0000-0002-9446-3756

Funding

Biotechnology and Biological Sciences Research Council BB/R007195/1Biotechnology and Biological Sciences Research Council BB/W016613/1Chinese Academy of Sciences XDB1360000CRUK C35050/A22284European FEDER Program 2017-EX002979European Union's NextGeneration EU programGuy Newton FundInstitut National du Cancer, Projets libres de Recherche PLBIO24-075National Natural Science Foundation of China 22207114National Natural Science Foundation of China 22477143National Research Development and Innovation Office K151375Région Centre-Val de LoireWellcome Trust 210634Wellcome Trust 223107Wellcome Trust 302632Zhongshan Municipal Bure of Science and Technology CXTD2022012
6 · The paper itself

Abstract

ADP-ribosylation is a conserved modification that uses NAD+ as a co-substrate to regulate essential cellular processes, such as genome stability and transcription, with Poly(ADP-ribose) Polymerases (PARPs) serving as the major catalyzing enzymes in humans. Historically defined as a protein post-translational modification, ADP-ribosylation on nucleic acids has been increasingly recognized in recent years, particularly in bacterial systems, but remains poorly understood in higher organisms. Here, we identify human PARP10 as a candidate enzyme that ADP-ribosylates nucleic acid bases, showing apparent activity on uracil bases in RNA, and a relatively weaker activity toward thymine bases in DNA. Furthermore, we show that human TARG1, a neurodegenerative disorder-linked protein previously reported to hydrolyse thymine base ADP-ribosylation, also efficiently reverses uracil base ADP-ribosylation (U-ADPr). To improve the efficient characterization of the enzymes for U-ADPr reversal, we developed chemical probes. Using these probes, we demonstrated that human TARG1 and TARG1-like macrodomain proteins are the efficient hydrolases for U-ADPr reversal in humans, Drosophila melanogaster, and bacterial homologues. The widespread distribution of U-ADPr hydrolases among different organisms suggests the potential evolutionary conservation of U-ADPr as a biological signal.

Indexed as

ADP-RibosylationPoly(ADP-ribose) PolymerasesRNAUracilAdenosine Diphosphate RiboseAnimalsDNADrosophila melanogasterHumansProto-Oncogene ProteinsThymineAdenosine Diphosphate RiboseDNAPARP10 protein, humanPoly(ADP-ribose) PolymerasesProto-Oncogene ProteinsRNAThymineUracil

Identifiers

PMID41914495
PMCPMC13036486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.